Developer docs
API playgroundTry for free, no card

Search company profiles

AVAC

Full company profile

uuid000qqek

Namestring
AVAC
Legal namestring
AVAC (AIDS Vaccine Advocacy Coalition)
Websiteurl
avac.org
Company typeenum
Private
Founded yearint
1995
Descriptiontext

AVAC (AIDS Vaccine Advocacy Coalition) is an international non-profit advocacy organization founded in 1995 and headquartered in New York, dedicated to accelerating the ethical development and equitable delivery of HIV prevention options as part of a broader pathway to global health equity. The organization operates as an independent 501(c)(3) and serves a multi-stakeholder audience that includes civil society advocates, key populations at higher HIV risk, adolescent girls and young women in high-prevalence settings, policymakers and funders, researchers and product developers, and people living with HIV. AVAC's core work spans advocacy, policy analysis, education, data tracking, and direct support for community engagement in clinical research.

AVAC's product portfolio is content- and data-centric rather than commercial software. It includes resource clearinghouses (PrEPWatch, STIWatch), the HIVResourceTracking investment database, the HIV Prevention Clinical Trials Database with global mapping, recurring publications (PxWire quarterly, Global Health Watch weekly, P-Values blog, AI & HIV Newsletter), the PxPulse podcast, and the People's Research Agenda framework. The organization also developed the Good Participatory Practice (GPP) Guidelines in 2007 with UNAIDS, now a global standard for stakeholder engagement in clinical trials across HIV, TB, COVID-19, and emerging pathogens. Ecosystem programs include CASPR, COMPASS Africa, CAALP, Media Science Cafés, and advocacy training pipelines (Advocacy Fellows, Advocacy Navigator, PxROAR, CureROAR).

AVAC's business model is grant- and donation-funded; all resources, databases, and tools are provided at no cost, and no products or services are sold. Revenue is not publicly disclosed. The organization actively operates across the United States and at least seven African countries (South Africa, Kenya, Zimbabwe, Uganda, Zambia, Tanzania, Malawi), and has demonstrated institutional independence by filing AVAC v. United States Department of State in February 2025 to challenge a US foreign aid freeze affecting HIV prevention funding.

Short descriptiontext

AVAC is an international non-profit, founded in 1995, that accelerates ethical development and equitable delivery of HIV prevention options through advocacy, resource databases (PrEPWatch, STIWatch, HIVResourceTracking), clinical trial tracking, and the Good Participatory Practice guidelines, serving civil society, key populations, policymakers, and researchers globally.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersNew York, United States
HQ citystring
New York
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
HIV prevention advocacy, global health policy, PrEP resource tracking, participatory research guidelines, HIV research advocacy
Industry4 codes
1Sexual Health & STI/HIV Prevention Health Departments
CodeHLAJAAALPrimaryYes
2Electronic Data Capture (EDC) Platforms
CodeHLACAOAAPrimaryNo
3Human Rights & Anti-Discrimination Organizations
CodeBPAGAFABPrimaryNo
4LGBTQ+ Rights & Advocacy Organizations
CodeBPAGAFAEPrimaryNo
NAICS code3 codes
  • Human Rights Organizations813311
  • Social Advocacy Organizations8133
  • Social Assistance624
SIC code1 code
  • Services-Social Services8300
Product category
HIV Prevention Advocacy
Marketing channels10 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components3 values
Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 14 records shown
1PrEPWatch
Description

A one-stop online clearinghouse for resources and information to help the global community effectively deliver proven methods of PrEP to everyone who needs it

avac.org
+13 more records
Core offering1 text field

AVAC advocates for the development of and global access to HIV prevention options, with a focus on products such as pre-exposure prophylaxis (PrEP). The organization delivers this through policy advocacy, online resource-tracking platforms (PrEPWatch, STIWatch, HIVResourceTracking), publications (AVAC Report newsletter), podcasts, and the Good Participatory Practice (GPP) guidelines used by researchers and trial sponsors.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

AVAC (AIDS Vaccine Advocacy Coalition) is an international non-profit advocacy organization, not a product company. AVAC does not offer a unified software product or platform. Instead, AVAC provides a portfolio of advocacy resources, databases, newsletters, podcasts, and guidelines focused on accelerating ethical development and equitable delivery of HIV prevention options. Key offerings include PrEPWatch (PrEP resource clearinghouse), STIWatch (STI resource tracker), HIVResourceTracking (R&D investment tracking), the HIV Prevention Clinical Trials Database, PxWire quarterly newsletter, PxPulse podcast, Global Health Watch weekly newsletter, and the Good Participatory Practice (GPP) Guidelines developed with UNAIDS.

Product and service1 record
1PrEPWatch
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Global non-profit advancing pediatric HIV prevention, treatment, and research; comparable as a HIV-focused advocacy and program delivery organization funded largely by US government and foundation grants.

TypeDirect peer
Description

Global partnership of civil society organizations working on HIV and human rights; comparable to AVAC as a coordinating advocacy body serving key populations and community-led organizations.

TypeDirect peer
Description

Activist research and policy non-profit focused on HIV, TB, and HCV; comparable as an advocacy and research-translation organization serving overlapping civil society and policymaker audiences.

TypeDirect peer
Description

NIH-funded clinical trials network conducting biomedical HIV prevention research; closely aligned with AVAC's HIV Prevention Clinical Trials Database and stakeholder engagement mission.

TypeDirect peer
Description

Leading HIV/AIDS-focused non-profit funding research and advocacy; directly comparable to AVAC as a private US 501(c)(3) advocating for HIV prevention, treatment, and cure science with public-policy engagement.

TypeDirect peer
Description

US-based HIV-focused advocacy and grantmaking coalition; shares the same civil-society advocacy, policy influence, and funder engagement model as AVAC.

TypeDirect peer
Description

Association of US state and territorial AIDS directors advancing HIV prevention, care, and policy; comparable to AVAC as a public-health advocacy organization targeting policymakers with evidence-based resources.

TypeDirect peer
Description

Global membership organization convening HIV professionals and producing the International AIDS Conference; comparable as the principal convening and knowledge-sharing body serving AVAC's researcher and policymaker segments.

TypeBroad incumbent
Description

United Nations joint programme coordinating the global HIV response; broader incumbent that co-developed AVAC's GPP guidelines and shapes the policy environment in which AVAC operates.

TypeBroad incumbent
Description

World Health Organization unit setting global normative guidance on HIV/STI prevention and treatment; broader institutional player whose PrEP and STI guidelines directly overlap with AVAC's resource platforms.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment6 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

AVAC

HIV Prevention Advocacyavac.org

AVAC is an international non-profit, founded in 1995, that accelerates ethical development and equitable delivery of HIV prevention options through advocacy, resource databases (PrEPWatch, STIWatch, HIVResourceTracking), clinical trial tracking, and the Good Participatory Practice guidelines, serving civil society, key populations, policymakers, and researchers globally.

What AVAC does

AVAC (AIDS Vaccine Advocacy Coalition) is an international non-profit advocacy organization founded in 1995 and headquartered in New York, dedicated to accelerating the ethical development and equitable delivery of HIV prevention options as part of a broader pathway to global health equity. The organization operates as an independent 501(c)(3) and serves a multi-stakeholder audience that includes civil society advocates, key populations at higher HIV risk, adolescent girls and young women in high-prevalence settings, policymakers and funders, researchers and product developers, and people living with HIV. AVAC's core work spans advocacy, policy analysis, education, data tracking, and direct support for community engagement in clinical research.

AVAC's product portfolio is content- and data-centric rather than commercial software. It includes resource clearinghouses (PrEPWatch, STIWatch), the HIVResourceTracking investment database, the HIV Prevention Clinical Trials Database with global mapping, recurring publications (PxWire quarterly, Global Health Watch weekly, P-Values blog, AI & HIV Newsletter), the PxPulse podcast, and the People's Research Agenda framework. The organization also developed the Good Participatory Practice (GPP) Guidelines in 2007 with UNAIDS, now a global standard for stakeholder engagement in clinical trials across HIV, TB, COVID-19, and emerging pathogens. Ecosystem programs include CASPR, COMPASS Africa, CAALP, Media Science Cafés, and advocacy training pipelines (Advocacy Fellows, Advocacy Navigator, PxROAR, CureROAR).

AVAC's business model is grant- and donation-funded; all resources, databases, and tools are provided at no cost, and no products or services are sold. Revenue is not publicly disclosed. The organization actively operates across the United States and at least seven African countries (South Africa, Kenya, Zimbabwe, Uganda, Zambia, Tanzania, Malawi), and has demonstrated institutional independence by filing AVAC v. United States Department of State in February 2025 to challenge a US foreign aid freeze affecting HIV prevention funding.

AVAC firmographics

Firmographics
Name
AVAC
Legal name
AVAC (AIDS Vaccine Advocacy Coalition)
Website
https://avac.org
Company type
Private
Founded year
1995
Operating status
Operating
Headcount range
11–50 employees
Short description
AVAC is an international non-profit, founded in 1995, that accelerates ethical development and equitable delivery of HIV prevention options through advocacy, resource databases (PrEPWatch, STIWatch, HIVResourceTracking), clinical trial tracking, and the Good Participatory Practice guidelines, serving civil society, key populations, policymakers, and researchers globally.
Ownership category
akta.pro rank

AVAC industry classification

Industry
Product category
HIV Prevention Advocacy
NAICS
Human Rights Organizations (813311), Social Advocacy Organizations (8133), Social Assistance (624)
SIC
Services-Social Services (8300)
akta.pro primary industry
Sexual Health & STI/HIV Prevention Health Departments (HLAJAAAL)
akta.pro secondary industries
Electronic Data Capture (EDC) Platforms (HLACAOAA), Human Rights & Anti-Discrimination Organizations (BPAGAFAB), LGBTQ+ Rights & Advocacy Organizations (BPAGAFAE)

Keywords

  • HIV prevention advocacy
  • Global health policy
  • PrEP resource tracking
  • Participatory research guidelines
  • HIV research advocacy

Where AVAC is headquartered

Location

Headquarters

HQ city
New York
HQ country
United States
HQ region
North America

Markets served

AVAC business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales

Distribution channels1 record

Marketing channels10 records

AVAC product offering

Product offering

Core offering

AVAC advocates for the development of and global access to HIV prevention options, with a focus on products such as pre-exposure prophylaxis (PrEP). The organization delivers this through policy advocacy, online resource-tracking platforms (PrEPWatch, STIWatch, HIVResourceTracking), publications (AVAC Report newsletter), podcasts, and the Good Participatory Practice (GPP) guidelines used by researchers and trial sponsors.

Product overview

AVAC (AIDS Vaccine Advocacy Coalition) is an international non-profit advocacy organization, not a product company. AVAC does not offer a unified software product or platform. Instead, AVAC provides a portfolio of advocacy resources, databases, newsletters, podcasts, and guidelines focused on accelerating ethical development and equitable delivery of HIV prevention options. Key offerings include PrEPWatch (PrEP resource clearinghouse), STIWatch (STI resource tracker), HIVResourceTracking (R&D investment tracking), the HIV Prevention Clinical Trials Database, PxWire quarterly newsletter, PxPulse podcast, Global Health Watch weekly newsletter, and the Good Participatory Practice (GPP) Guidelines developed with UNAIDS.

Differentiator

Problem solved

Functional benefit

Brands

  • PrEPWatch: A one-stop online clearinghouse for resources and information to help the global community effectively deliver proven methods of PrEP to everyone who needs it
  • STIWatch
  • HIVResourceTracking
  • PxPulse
  • PxWire
  • Global Health Watch
  • The Choice Agenda
  • CASPR (Coalition to Accelerate and Support Prevention Research)
  • COMPASS Africa
  • Good Participatory Practice (GPP)
  • CAALP (Coalition to Accelerate Access to Long-Acting PrEP)
  • PxROAR and CureROAR
  • AVAC Advocacy Fellows Program
  • Advocacy Navigator

Products and services

  • PrEPWatch

Companies that use AVAC

Customer profile

Segments6 records

Ideal customer profiles2 records

AVAC technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

AVAC partnerships and signals

Strategic signal

Recent moves6 records

Expansion highlights5 records

AVAC competitors and assessment

Company assessment

Direct peers

  • Elizabeth Glaser Pediatric AIDS Foundation (EGPAF): Global non-profit advancing pediatric HIV prevention, treatment, and research; comparable as a HIV-focused advocacy and program delivery organization funded largely by US government and foundation grants.
  • Frontline AIDS: Global partnership of civil society organizations working on HIV and human rights; comparable to AVAC as a coordinating advocacy body serving key populations and community-led organizations.
  • Treatment Action Group (TAG): Activist research and policy non-profit focused on HIV, TB, and HCV; comparable as an advocacy and research-translation organization serving overlapping civil society and policymaker audiences.
  • HPTN (HIV Prevention Trials Network): NIH-funded clinical trials network conducting biomedical HIV prevention research; closely aligned with AVAC's HIV Prevention Clinical Trials Database and stakeholder engagement mission.
  • amfAR (Foundation for AIDS Research): Leading HIV/AIDS-focused non-profit funding research and advocacy; directly comparable to AVAC as a private US 501(c)(3) advocating for HIV prevention, treatment, and cure science with public-policy engagement.
  • AIDS United: US-based HIV-focused advocacy and grantmaking coalition; shares the same civil-society advocacy, policy influence, and funder engagement model as AVAC.
  • NASTAD: Association of US state and territorial AIDS directors advancing HIV prevention, care, and policy; comparable to AVAC as a public-health advocacy organization targeting policymakers with evidence-based resources.
  • International AIDS Society (IAS): Global membership organization convening HIV professionals and producing the International AIDS Conference; comparable as the principal convening and knowledge-sharing body serving AVAC's researcher and policymaker segments.

Broad incumbents

  • UNAIDS: United Nations joint programme coordinating the global HIV response; broader incumbent that co-developed AVAC's GPP guidelines and shapes the policy environment in which AVAC operates.
  • WHO Department of Global HIV, Hepatitis and STIs: World Health Organization unit setting global normative guidance on HIV/STI prevention and treatment; broader institutional player whose PrEP and STI guidelines directly overlap with AVAC's resource platforms.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

AVAC social profiles

Digital presence

AVAC financial estimates

Financial estimate

Revenue estimate

Valuation estimate

AVAC leadership team

Management profile

Number of profiles

Profiles1 record

AVAC funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

AVAC M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AVAC

What does AVAC do?

AVAC advocates for the development of and global access to HIV prevention options, with a focus on products such as pre-exposure prophylaxis (PrEP). The organization delivers this through policy advocacy, online resource-tracking platforms (PrEPWatch, STIWatch, HIVResourceTracking), publications (AVAC Report newsletter), podcasts, and the Good Participatory Practice (GPP) guidelines used by researchers and trial sponsors.

Is AVAC a public or private company?

AVAC is a private company. It is classified as nonprofit foundation owned and is currently operating.

When was AVAC founded?

AVAC was founded in 1995. It employs 11 to 50 people.

Where is AVAC based?

AVAC is headquartered in New York, United States, in the North America region.

Who are AVAC's main competitors?

Direct peers on record are Elizabeth Glaser Pediatric AIDS Foundation (EGPAF), Frontline AIDS, Treatment Action Group (TAG), HPTN (HIV Prevention Trials Network), amfAR (Foundation for AIDS Research), AIDS United, NASTAD and International AIDS Society (IAS). Broad incumbents are UNAIDS and WHO Department of Global HIV, Hepatitis and STIs.

Does AVAC have an API?

No public API is recorded for AVAC.

What industry is AVAC in?

AVAC's product category is HIV Prevention Advocacy. Its primary akta.pro industry code is HLAJAAAL, Sexual Health & STI/HIV Prevention Health Departments, with a secondary code of HLACAOAA, Electronic Data Capture (EDC) Platforms. Its NAICS code is 813311 and its SIC code is 8300.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR Newswire2018 Omololu Falobi Award for Excellence in HIV Prevention Research Community Advocacy Celebrates a "Real Powerhouse" Young PrEP AdvocateGcobisa Madlolo, a South African activist and early adopter of pre-exposure prophylaxis (PrEP), received the fifth Omololu Falobi Award for Excellence in HIV Prevention Research Community Advocacy at the opening session of the HIVR4P Conference in Madrid on October 22, 2018. The award recognizes courageous young people who participate in clinical trials and advocate for new biomedical HIV prevention options, honoring the legacy of Nigerian activist Omololu Falobi. The award is presented annually by a coalition of HIV prevention advocacy organizations including AMAG, AVAC, IRMA, JAAIDS, and NHVMAS.PR NewswireTwo clinical trials offer first evidence that vaginal ring may be important HIV prevention option for women; AVAC says donors, researchers, regulators and communities must act swiftly to determine futResults from two large-scale clinical trials in Africa (ASPIRE and The Ring Study) show that a monthly vaginal ring containing the antiretroviral drug dapivirine reduced the risk of HIV transmission by 27-31% overall, with substantially higher efficacy of 37-56% among women over 21 who used the ring consistently. AVAC, an HIV prevention advocacy organization, is calling on researchers, donors, regulators, and communities to act swiftly to determine the ring's regulatory pathway and address remaining questions about adherence, particularly among younger women. Both trials found the ring was safe to use, and open-label extension studies are being planned to help guide decisions about potential regulatory approval and eventual rollout.